R econstitution: Quick and Easy

Page 1 of 2
R econstitution: Quick and Easy
It takes 2—mix the DTaP-IPVa and Hibb components
together to make Pentacel vaccine1
Combine the DTaP-IPV and Hib components
Helpful hint
Careful and complete syringe
loading will ensure proper dosing.
• Gently shake the vial of the liquid
DTaP-IPV component
• Insert the needle, invert the vial,
and withdraw the entire contents
of liquid DTaP-IPV
• Insert the needle into the stopper of
the vial of lyophilized Hib powder and
inject the entire liquid contents
Withdraw Pentacel vaccine
Helpful hint
Use the bull’s-eye in the rubber
stopper of the vial for proper
needle insertion.
Helpful hint
Rotate the inverted vial until the
longer channel in the stopper is
facing you. Ensure the bevel of the
needle is visible in the channel and
is fully submerged. The channel
should be clear of air bubbles.
• To reconstitute Pentacel vaccine,
gently swirl the vial with the needle
inserted to mix thoroughly
• Invert the vial, position the needle bevel
within the longer channel as shown, and
withdraw 0.5mL for administration
a
TaP = Diphtheria, tetanus, and acellular pertussis;
D
IPV = Inactivated poliovirus. b Hib = Haemophilus influenzae type b.
Please click here for Important Safety Information.
Page 2 of 2
IMPORTANT SAFETY INFORMATION
INDICATION
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis,
and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use as a
4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).
SAFETY INFORMATION
The most common local and systemic adverse reactions to Pentacel vaccine include injection site
redness, swelling, and tenderness; fever, fussiness, and crying. Other adverse reactions may occur.
Known systemic hypersensitivity reaction to any component of Pentacel vaccine or a life-threatening
reaction after previous administration of the vaccine or a vaccine containing the same substances are
contraindications to vaccination.
The decision to give Pentacel vaccine should be based on the potential benefits and risks; if Guillain-Barré
syndrome (GBS) has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid;
or if adverse events have occurred in temporal relation to receipt of pertussis-containing vaccine.
Encephalopathy within 7 days of administration of a previous dose of a pertussis-containing vaccine
or a progressive neurologic disorder is a contraindication. Vaccination with Pentacel vaccine may
not protect all individuals.
Before administering Pentacel vaccine, please click here for full Prescribing Information.
To order Pentacel vaccine, log onto VaccineShoppe.com® or call 1-800-VACCINE (1-800-822-2463).
For more information, please visit pentacel.com.
CPT®c Code: 90698
CPT component-based vaccine administration codes became effective January 2011. These codes
help to account for the work and practice expenses associated with the administration of vaccines
when counseling is provided.
c
CPT = Current Procedural Terminology is a registered trademark of the American Medical Association.
Pentacel vaccine is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed
by Sanofi Pasteur Inc.
Reference: 1. Pentacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2011.
Sanofi Pasteur. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofipasteur.us
MKT23710-1-1R
© 2012 Sanofi Pasteur Inc.
1/12